Arcus Biosciences, Inc.
RCUS evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Market Cap:
- $3.70B
- Lead Asset:
- AB308 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for RCUS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RCUS
Arcus Biosciences, Inc. (RCUS) is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory/autoimmune diseases, with a pipeline spanning Phase 1 to Phase 3 and key partnerships with Gilead and Taiho.
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Market Cap
$3.70B
Cash Runway
—
Lead Asset
AB308 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 25 clinical trials for Arcus Biosciences, Inc..
Arcus Biosciences, Inc. (RCUS) is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory/autoimmune diseases, with a pipeline spanning Phase 1 to Phase 3 and key partnerships with Gilead and Taiho.
- Cash & equivalents of $150.0M as of 2026-06-30 [sec]
- Net loss of -$91.0M as of 2026-06-30 [sec]
- Shareholders' equity of $464.0M as of 2026-06-30 [sec]
- Total debt of $100.0M as of 2026-06-30 [sec]
- Phase 3 programs include domvanalimab (anti-TIGIT), zimberelimab (anti-PD-1), and casdatifan (HIF-2α inhibitor) [pipeline]
What works
- Multiple Phase 3 programs (domvanalimab, zimberelimab, casdatifan) indicate a deep late-stage pipeline [pipeline]
- Strong partnerships with Gilead (co-development, U.S. co-promotion) and Taiho (regional licenses) provide non-dilutive capital and commercial reach [pipeline]
- Company has demonstrated rapid advancement from program initiation to IND in as short as 18 months [news · published 2026-05-05]
What to weigh
- Net loss of -$91.0M as of 2026-06-30 indicates significant ongoing operating expenses [sec]
- No approved products yet; all programs are clinical-stage, with no marketed revenue [pipeline]
- Competitive landscape for key assets (e.g., CD73, anti-TIGIT, HIF-2α) includes large pharma with deeper resources [pipeline]
From the filings
Quoted directly from source documents.
Phase 3 status of domvanalimab
“Domvanalimab Generic Name: anti-TIGIT antibody Indication: Advanced Upper Gastrointestinal Tract Adenocarcinoma; Solid Tumor, Unspecified, Adult; Non Small Cell Lung Cancer Phase: Phase 3”
Casdatifan is a HIF-2α inhibitor in Phase 3
“Casdatifan Generic Name: Casdatifan Indication: Clear Cell Renal Cell Carcinoma; Healthy Participants; Metastatic Clear Cell Renal Cell Carcinoma Phase: Phase 3 Mechanism of Action: HIF-2α inhibitor”
Catalyst timeline
- 2022-11-21 · Phase 3 Start: Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Gastric/GEJ/Esophageal Adenocarcinoma — A randomized, open-label, multicenter Phase 3 trial initiated; results will inform registrational potential.
- 2023-07-01 · Phase 2 Start: SBRT, Adenosine Signaling Modulation (AB680, AB928), and Immune Checkpoint Inhibition (AB122) for Hormone Sensitive Prostate Cancer — Single-arm Phase II study testing combination therapy; may support later-stage development.
Risks & what to watch (3)›
Key risks
- No approved products — All pipeline candidates are in clinical stages; no marketed revenue to offset R&D costs [pipeline]
- Significant net loss — Net loss of -$91.0M as of 2026-06-30 indicates high cash burn rate [sec]
- Intense competition — Key programs face competition from large pharma (e.g., Merck, AstraZeneca, Bristol-Myers Squibb) [pipeline]
What to watch
- At least three data readouts for casdatifan expected during 2026 [news · published 2026-01-07]
- Phase 3 STAR-121 study of domvanalimab combo analysis planned for Q1/Q2 2026 [news · published 2026-01-07]
- Clinical trial collaboration with Summit Therapeutics for casdatifan; data expected by mid-2027 [news · published 2026-07-22]
Sources: Catalysts · News · Pipeline · Generated October 12, 2026 · How we verify sources →
Run Arcus Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Arcus Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.99 · 0% dilution
Lead: Phase 3
6 candidates
No upcoming catalysts tracked
0 buys · 10 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
210
Total value held
$2.56B
| Holder | Shares | Value |
|---|---|---|
| gilead sciences, inc. | 31,424,760 | $678.8M |
| blackrock, inc. | 15,226,475 | $328.9M |
| wellington management group llp | 6,089,516 | $131.5M |
| state street corp | 5,412,901 | $116.9M |
| suvretta capital management, llc | 5,030,993 | $108.7M |
| vanguard portfolio management llc | 4,272,056 | $92.3M |
| vanguard capital management llc | 3,856,725 | $83.3M |
| woodline partners lp | 3,777,798 | $81.6M |
| marshall wace, llp | 3,761,437 | $81.2M |
| siren, l.l.c. | 3,007,077 | $65.0M |
Showing top 10 of 210 institutional holders of Arcus Biosciences, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 11.2%
- Days to cover
- 7.6
- Shares short
- 9,876,250
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RCUS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Arcus Biosciences, Inc.?
Arcus Biosciences, Inc. (RCUS) is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory/autoimmune diseases, with a pipeline spanning Phase 1 to Phase 3 and key partnerships with Gilead and Taiho.
What is Arcus Biosciences, Inc.'s lead drug candidate?
Arcus Biosciences, Inc.'s most advanced tracked candidate is AB308 (Phase 1) for Advanced Solid Tumor.
Who is the CEO of Arcus Biosciences, Inc.?
Dr. Terry J. Rosen Ph.D. is the chief executive officer of Arcus Biosciences, Inc. (RCUS).
Where is Arcus Biosciences, Inc. headquartered?
Arcus Biosciences, Inc. (RCUS) is headquartered in Hayward, CA, United States.
What therapeutic areas does Arcus Biosciences, Inc. focus on?
Arcus Biosciences, Inc. develops therapies across Oncology, Immunology, Metabolic, Nephrology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.